产品特点
Issued: February 2013
AN: 01533/2011
Page 1 of 5
_ _
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Butagran Equi, 200 mg/g, oral powder for horses.
Butagran Equi, 200 mg/g (DK)
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Per g:
_ACTIVE SUBSTANCE: _
Phenylbutazone
200 mg
_Excipients: _
For a full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Oral powder.
White powder.
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The product is indicated for the treatment of musculo-skeletal conditions where
relief from pain and a reduction in the associated inflammation is required e.g. in
lameness associated with osteoarthritic conditions, bursitis, laminitis and soft
tissue inflammation, particularly where continued mobility is considered desirable.
It is also of value in limiting post-surgical inflammation, myositis and other soft
tissue inflammation.
The product can be used as an anti-pyretic where this is considered advisable e.g.
in viral respiratory infections.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active ingredient.
Use is contraindicated in animals suffering from cardiac, hepatic or renal disease,
where there is the possibility of gastrointestinal ulceration or bleeding or where
there is evidence of a blood dyscrasia.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The clinical effects of phenylbutazone can be evident for at least three days
following cessation of therapy. This should be borne in mind when examining
horses for soundness.
Issued: February 2013
AN: 01533/2011
Page 2 of 5
_ _
FEI regards phenylbutazone as
阅读完整的文件